Translational Development Acquisition CORP. (TDACW) — SEC Filings

Overview

Translational Development Acquisition CORP. (TDACW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 14, 2025: Translational Development Acquisition Corp. (TDACW) reported a net income of $1,660,122 for the three months ended September 30, 2025, a significant improvement from a net loss of $61,283 in the same period of 2024. For the nine months ended September 30, 2025, the company achieved a net income of $

Sentiment Summary

Across 11 filings, the sentiment breakdown is: 10 neutral, 1 mixed. The dominant filing sentiment for Translational Development Acquisition CORP. is neutral.

Filing Type Overview

Translational Development Acquisition CORP. (TDACW) has filed 3 10-Q, 4 8-K, 1 10-K, 2 S-1/A, 1 S-1 with the SEC between Oct 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (11)

• TDACW Swings to Profit on Trust Account Gains, SPAC Deadline Looms — 10-Q · Nov 14, 2025 Risk: high
  Translational Development Acquisition Corp. (TDACW) reported a net income of $1,660,122 for the three months ended September 30, 2025, a significant improvement
• TDACU Files 8-K on Share and Warrant Unit Structure — 8-K · Aug 14, 2025 Risk: low
  On August 8, 2025, Translational Development Acquisition Corp. (TDACU) filed an 8-K report detailing events related to its units, which consist of Class A ordin
• Translational Development Acquisition Corp. Q2 2025 10-Q Filed — 10-Q · Aug 14, 2025 Risk: medium
  Translational Development Acquisition Corp. filed its 10-Q for the period ending June 30, 2025. The company's Class A ordinary shares subject to redemption were
• Translational Development Acquisition Corp. 10-Q Filing — 10-Q · May 15, 2025 Risk: low
  Translational Development Acquisition Corp. filed its 10-Q for the period ending March 31, 2025. The filing details financial information including ordinary sha
• Translational Development Acquisition Corp. Files 2024 10-K — 10-K · Mar 31, 2025 Risk: low
  Translational Development Acquisition Corp. filed its 10-K for the fiscal year ending December 31, 2024. The company, identified by Central Index Key 0001926599
• Translational Development Acquisition Corp. Files 8-K — 8-K · Feb 14, 2025 Risk: low
  Translational Development Acquisition Corp. filed an 8-K on February 14, 2025, reporting on other events and financial statements. The company, incorporated in
• Translational Development Acquisition Corp. Files 8-K — 8-K · Dec 31, 2024 Risk: low
  Translational Development Acquisition Corp. filed an 8-K on December 31, 2024, reporting an event that occurred on December 24, 2024. The filing details the com
• TDACU Closes $100M IPO — 8-K · Dec 27, 2024 Risk: medium
  Translational Development Acquisition Corp. (TDACU) announced on December 20, 2024, the closing of its initial public offering of 10,000,000 units at $10.00 per
• Translational Development Acquisition Corp. Files S-1/A Amendment — S-1/A · Dec 19, 2024 Risk: medium
  Translational Development Acquisition Corp. filed an S-1/A amendment on December 19, 2024, for its registration statement. The company, incorporated in the Caym
• Translational Development Acquisition Corp. Files S-1/A Amendment — S-1/A · Nov 20, 2024 Risk: low
  Translational Development Acquisition Corp. filed an S-1/A amendment on November 20, 2024, related to its registration statement (No. 333-282763). The company,
• Translational Development Acquisition Corp. Files S-1 — S-1 · Oct 22, 2024 Risk: medium
  Translational Development Acquisition Corp. filed an S-1 registration statement on October 22, 2024, for a proposed public offering. The company, incorporated i

Risk Profile

Risk Assessment: Of TDACW's 11 recent filings, 1 were flagged as high-risk, 4 as medium-risk, and 6 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Translational Development Acquisition CORP.'s most recent 10-Q filing (Nov 14, 2025):

• Revenue: $0
• Net Income: $4.77M
• EPS: N/A
• Debt-to-Equity: N/A
• Cash Position: $47,150
• Operating Margin: N/A
• Total Assets: $179.98M
• Total Debt: $6.46M

Key Executives

• Michael B. Hoffman

Industry Context

Translational Development Acquisition Corp. operates as a special purpose acquisition company (SPAC). The SPAC industry is characterized by its focus on identifying and merging with private companies to take them public. Key trends include increased regulatory scrutiny, a competitive landscape for identifying attractive targets, and a finite timeframe for completing a business combination before liquidation.

Top Tags

spac (8) · SPAC (2) · 10-Q (2) · financials (2) · filing-update (2) · ipo (2) · registration (2) · Financial Performance (1) · Trust Account (1) · Business Combination (1)

Key Numbers

• Net Income: $4.77M — for the nine months ended September 30, 2025, a significant increase from a $62,968 net loss in 2024.
• Dividends and Interest Income: $5.67M — earned on marketable securities in Trust Account for the nine months ended September 30, 2025, driving profitability.
• General and Administrative Costs: $782K — for the nine months ended September 30, 2025, up from $62,968 in 2024, indicating increased operational expenses.
• Trust Account Assets: $179.9M — as of September 30, 2025, representing the primary asset base for a Business Combination.
• Cash: $47,150 — as of September 30, 2025, a decrease from $438,174 at December 31, 2024, highlighting limited operating liquidity.
• Business Combination Deadline: June 24, 2026 — the date by which the company must complete a merger or liquidate.
• Class A Ordinary Shares: 17,250,000 — outstanding and subject to possible redemption as of September 30, 2025.
• Redemption Value per Share: $10.43 — as of September 30, 2025, for Class A ordinary shares.
• Warrant Exercise Price: 11.50 — The price at which each warrant can be exercised to purchase one Class A ordinary share.
• Reporting Period End Date: 20250630 — Indicates the end of the fiscal quarter for this 10-Q filing.
• Filing Date: 20250814 — The date the 10-Q was officially submitted to the SEC.
• Previous Quarter End Date: 2024-12-31 — Provides a point of comparison for financial performance.
• Prior Year Quarter End Date: 2024-03-31 — Allows for year-over-year performance comparison.
• Financial Value: 4,657,500 — A significant financial figure reported in the filing.
• IPO Gross Proceeds: $100.0M — Capital raised from the initial public offering.

Related Companies

TDACU

Frequently Asked Questions